Vesnarinone limits infarct size via adenosine-dependent mechanisms in the canine heart

Circulation

Volumn 95, Issue 8, 1997, Pages 2108-2114

  Kitakaze, Masafumi ^a   Minamino, Tetsuo ^a   Funaya, Hiroharu ^a   Node, Koichi ^a   Shinozaki, Yoshiro ^b   Mori, Hidezo ^b   Hori, Masatsugu ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

adenosine; coronary disease; ischemia; myocardial infarction; reperfusion

Indexed keywords

ADENOSINE; ADENOSINE DERIVATIVE; ADENOSINE RECEPTOR BLOCKING AGENT; DIPYRIDAMOLE; ECTO 5' NUCLEOTIDASE; ESTERASE INHIBITOR; PIPERANOMETOZINE; THEOPHYLLINE DERIVATIVE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVITY; HEART INFARCTION SIZE; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HEART PROTECTION; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY;

EID: 0030896816     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.95.8.2108     Document Type: Article

References (45)

1. OPC-8212 Multicenter Research Group. A placebo-controlled, randomized, double-blind study of OPC-8212 in patients with mild chronic heart failure. Cardiovasc Drugs Ther. 1990;4:419-426.
2. Sasayama S. What do the new inotropic drugs have to offer? Cardiovasc Drugs Ther. 1992;6:15-18.
3. Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, Strobeck JE, Hendrix GH, Powers ER, Bain RP, White BG. Effects of vesnarinone on morbidity and mortality in patients with heart failure. N Engl J Med. 1993;329:149-155.
4. Maruyama Y, Nishioka O, Watanabe J, Keitoku M, Satoh S, Isoyama S, Ashikawa K, Inooka E, Takishima T. Effects of OPC-8212, a new positive inotropic agent, and dobutamine on left ventricular global and ischemic regional functions and coronary hemodynamics under coronary artery stenosis. J Cardiovasc Pharmacol. 1986;8:161-169.
5. Uretsky BF, Jessup M, Konstam MA. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure: lack of benefit compared with placebo. Circulation. 1990;82:774-780.
6. The Xamoterol in Severe Heart Failure Study Group. Xamoterol in severe heart failure. Lancet. 1990;336:1-6.
7. Packer M, Carver JR, Rodeheffer RJ. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med. 1991;325: 1468-1475.
8. 2+ channels in ventricular myocytes of guinea pig. J Cardiovasc Pharmacol. 1989;13:812-819.
9. Matsui S, Matsumori A, Matoba Y, Uchida A, Sasayama S. Treatment of virus-induced myocardial injury with a novel immunomodulating agent, vesnarinone. J Clin Invest. 1994;94:1212-1217.
10. Matsumori A, Shioi T, Yamada T, Matsui S, Sasayama S. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994;89:955-958.
11. Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, Schomig A. Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation. 1995;92: 748-755.
12. Kumakura T, Takase K, Terada N, Gelfand EW. Vesnarinone inhibits nucleoside and nucleobase transport. Life Sci. 1995;57: 75-81.
13. Hori M, Kitakaze M. Adenosine, the heart, and coronary circulation. Hypertension. 1991;18:565-574.
14. Olafsson B, Forman MB, Puett DW, Pou A, Cates CU, Friesinger GC, Virmani R. Reduction of reperfusion injury in the canine preparation by intracoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation. 1987;76: 1135-1145.
15. 1 adenosine receptors in rabbit heart. Circulation. 1991;84:350-356.
16. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada T. Ischemic preconditioning increases adenosine release and 5′-nucleotidase activity during myocardial ischemia and reperfusion in dogs: implication for myocardial salvage. Circulation. 1993;87: 208-215.
17. Kitakaze M, Hori M, Morioka T, Minamino T, Takashima S, Sato H, Shinozaki Y, Chujo M, Mori H, Inoue M, Kamada T. Infarct size-limiting effect of ischemic preconditioning is blunted by inhibition of 5′-nucleotidase activity and attenuation of adenosine release. Circulation. 1994;89:1237-1246.
18. 1-adrenoceptor activation mediates the infarct size limiting effect of ischemic preconditioning through augmentation of 5′-nucleotidase activity and adenosine release. J Clin Invest. 1994;93:2197-2205.
19. Kitakaze M, Minamino T, Node K, Komamura K, Hori M. Activation of ecto-5′-nucleotidase and cardioprotection of ischemic preconditioning. Basic Res Cardiol. 1996;91:23-26. Brief review.
20. 1-Adrenoceptor activity regulates release of adenosine from the ischemic myocardium in dogs. Circ Res. 1987;60:631-639.
21. Mori H, Haruyama S, Shinozaki Y, Okino H, Iida A, Takanashi R, Sakura I, Husseini W, Payne B, Hoffman JIE. New nonradioactive microspheres and more sensitive x-ray fluorescence to measure regional blood flow. Am J Physiol. 1992;263:H1946-H1957.
22. Hori M, Inoue M, Kitakaze M, Koretsune Y, Iwai K, Tamai J, Ito H, Kitabatake A, Sato T, Kamada T. Role of adenosine in hyperemic response of coronary blood flow in microembolization. Am J Physiol. 1986;250:H509-H518.
23. Yamane R, Nakamura T, Matuura E, Ishige H, Fujimoto M. A simple and sensitive radioimmunoassay for adenosine. J Immunoassay. 1991;12:501-519.
24. Smith K, Varon HH, Race GJ, Paulson DL, Urshel HC, Mallams JT. Serum 5′-nucleotidase in patients with tumor in the liver. Cancer. 1965;19:1281-1285.
25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with Folin phenol reagent. J Biol Chem. 1951;193: 265-275.
26. Winer BJ. Statistical Principles in Experimental Design. 2nd ed. New York, NY: McGraw-Hill Inc; 1982:1-907.
27. Snedecor GW, Cochran WG. Statistical Methods. 6th ed. Ames, Iowa: Iowa State University Press; 1972:258-298.
28. Bürger R. Thermodynamic state of cytosolic adenylates in guinea pig myocardium: energy-linked adaptive changes in free adenylates and purine nucleosides release. In: Gerlach E, Becker BF, eds. Topics and Perspective in Adenosine Research. Berlin/Heidelberg: Springer-Verlag; 1987:223-234.
29. Forrester T, Williams CA. Release of adenosine triphosphate from isolated adult heart cells in response to hypoxia. J Physiol. 1977; 268:371-390.
30. Borst MM, Schräder J. Adenine nucleotides release from isolated perfused guinea pig hearts and extracellular formation of adenosine. Circ Res. 1991;84:797-806.
31. Iijima T, Taria N. Membrane current changes responsible for the positive effect of OPC-8212, a new positive inotropic agent, in single ventricular cells of guinea pig heart. J Pharmacol Exp Ther. 1987; 240:657-662.
32. Lathrop DA, Schwartz A. Evidence for possible increase in sodium channel open time and involvement of Na/Ca exchange by a new positive inotropic drug: OP-8212. Eur J Pharmacol. 1985;117: 391-392.
33. Inoue M, Hori M, Nakajima S. Kitakaze M, Fukunami M, Ishida Y, Abe H. Effects of 3,4-dihydro-6-[(3-4-dimethoxybenzoyl)-1-piperazinyl]-2(1H)-quinolinone (OPC-8212), new inotropic agent, on cardiotonic activity and coronary hemodynamics. Arzneimittelforschung. 1985;34:355-359.
34. 1-Adrenoceptor activation increases ectosolic 5′-nucleotidase activity and adenosine release in rat cardiomyocytes by activating protein kinase C. Circulation. 1995;91:2226-2234.
35. Dorheim TA, Hoffman A, Van Wylen DGL, Mentzer RM Jr. Enhanced interstitial fluid adenosine attenuates myocardial stunning. Surgery. 1991;110:136-145.
36. Babbitt TG, Virmani R, Norton R Jr, Forman MB. Adenosine administration during repercussion following 3 hours of ischemia: effects on infarct size, ventricular function, and regional myocardial blood flow. Am Heart J. 1990;120:808-818.
37. Gruber HE, Hoffer ME, McAllister DR, Laikand PK, Lane TA, Schmid-Schoenbein RL, Engler RL. Increased adenosine concentration in blood from ischemic myocardium by AICA riboside: effects on flow, granulocyte, and injury. Circulation. 1989;80: 1400-1411.
38. Norton ED, Jackson EK, Virmani R, Forman MB. Effect of intravenous adenosine on myocardial reperfusion injury in a model with low myocardial collateral blood flow. Am Heart J. 1991;122: 1283-1291.
39. 2 receptors prevent myocardial stunning. Circulation. 1990; 82(suppl III):III-37. Abstract.
40. Richardt G, Wassa W, Kranzhofer R, Mayer E, Schömig A. Adenosine inhibits exocytotic release of endogenous noradrenaline in rat heart: a protective mechanism in early myocardial ischemia. Circ Res. 1987;61:117-123.
41. Isenberg G, Cerbai E, Klockner U. Ionic channels and adenosine in isolated heart cells. In: Gerlach E, Becker BF, eds. Topics and Perspective in Adenosine Research. Berlin/Heidelberg: Springer-Verlag; 1987:323-335.
42. Sato H, Hori M, Kitakaze M, Takashima S, Inoue M, Kitabatake A, Kamada T. Endogenous adenosine blunts β-adrenoceptor-mediated inotropic response in hypoperfused canine myocardium. Circulation. 1992;85:1594-1603.
43. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R. Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest. 1986;78:760-770.
44. Agarwal KC, Zielinski BA, Maitra RS. Significance of plasma adenosine in the antiplatelet activity of forskolin: potentiation by dipyridamole and dilazep. Thromb Haemost. 1989;61:106-110.
45. Kitakaze M, Hori M, Sato H, Takashima S, Kitabatake A, Inoue M, Kamada T. Endogenous adenosine inhibits platelet aggregation during myocardial ischemia. Circ Res. 1991;69:1402-1408.